Author

Fatemah O. F. O. Alshammari

Observed names: Fatemah O F O Alshammari, Fatemah O. F. O. Al-Shammari, Fatemah O.F.O. Alshammari, Fatemah OFO Alshammari

Institution: Public Authority for Applied Education and Training

Observed institutions: University of Bradford, Public Authority for Applied Education and Training

ORCID: 0000-0002-5640-9601

Observed ORCID: 0000-0002-5640-9601

OpenAlex ID: A5078621989

Profiling of CYP4Z1 and CYP1B1 expression in bladder cancers

2021 · Yousef M. Al-saraireh, Fatemah O. F. O. Alshammari, et al. · Scientific Reports · 40

PDF

Cytochrome P450 1B1 Overexpression in Cervical Cancers: Cross-sectional Study

2021 · Fatemah O F O Alshammari, Yousef M Al-saraireh, et al. · Interactive Journal of Medical Research · 26

PDF

Cytochrome 4Z1 Expression Is Correlated with Poor Prognosis in Patients with Cervical Cancer

2021 · Yousef M. Al-saraireh, Fatemah O. F. O. Alshammari, et al. · Current Oncology · 22

PDF

Phytochemical characterization and anti-cancer properties of extract of Ephedra foeminea (Ephedraceae) aerial parts

2022 · Yousef M. Al-saraireh, Ahmed M.M. Youssef, et al. · Tropical Journal of Pharmaceutical Research · 19

PDF

Cytochrome 4Z1 Expression is Associated with Poor Prognosis in Colon Cancer Patients

2021 · Yousef M Al-saraireh, Fatemah OFO Alshammari, et al. · OncoTargets and Therapy · 18

PDF

Cytochrome 4Z1 Expression is Associated with Unfavorable Survival in Triple-Negative Breast Cancers

2021 · Yousef M Al-saraireh, Fatemah OFO Alshammari, et al. · Breast Cancer Targets and Therapy · 18

PDF

Glypican-1 Overexpression in Different Types of Breast Cancers

2021 · Fatemah OFO Alshammari, Yousef M Al-Saraireh, et al. · OncoTargets and Therapy · 18

PDF

Targeting Cytochrome P450 Enzymes in Ovarian Cancers: New Approaches to Tumor-Selective Intervention

2023 · Yousef M. Al-saraireh, Fatemah O. F. O. Alshammari, et al. · Biomedicines · 17

PDF

Glypican-3 Differentiates Intraductal Carcinoma and Paget’s Disease from Other Types of Breast Cancer

2022 · Fatemah OFO Alshammari, Anas O. Satari, et al. · Medicina · 13

PDF

Synthesis and Biological Evaluation of Cyclobutane-Based β3 Integrin Antagonists: A Novel Approach to Targeting Integrins for Cancer Therapy

2023 · Mark Sutherland, Andrew Gordon, et al. · Cancers · 10

PDF

Cytochrome 4Z1 Expression Connotes Unfavorable Prognosis in Ovarian Cancers

2022 · Yousef M. Al-saraireh, Fatemah O. F. O. Alshammari, et al. · Medicina · 9

PDF

Screening of Glypican-6 Expression in Benign, Primary and Metastatic Colon Cancers

2021 · Yousef M Al-Saraireh, Fatemah OFO Alshammari, et al. · Clinical Medicine Insights Oncology · 5

Expression and Clinical Significance of Cytochrome 1B1 in Bone Sarcomas

2025 · Belal Al-zu’bi, Fatemah OFO Alshammari, et al. · Pharmaceuticals · 2

PDF

Immunohistochemical and Transcriptomic Assessment of Cytochrome 2J2 in Prostate and Renal Cancer

2026 · Yousef M. Al-saraireh, Fatemah OFO Alshammari, et al. · Cancers · 1

CYP4B1 Expression in Breast Cancer: An Immunohistochemical Study with Complementary in silico Analyses

2026 · Yousef M Al-saraireh, Fatemah OFO Alshammari, et al. · Breast Cancer Targets and Therapy · 1

PDF

Glypican-1 in Rhabdomyosarcoma: A Multi-omics Exploration of a Targetable Biomarker

2026 · Belal Al-zu'bi, Fatemah OFO Alshammari, et al. · Recent Patents on Anti-Cancer Drug Discovery

Screening of cytochrome CYP26A1 expression in different bone tumors

2026 · Belal Al-zu’bi, Fatemah O. F. O. Alshammari, et al. · BMC Cancer

An immunohistopathological and functional investigation of β3 integrin antagonism as a therapeutic strategy in cancer. Characterisation, development, and utilisation of preclinical cancer models to investigate novel ¿3 integrin anatgonists.

2014 · Fatemah O. F. O. Alshammari · Bradford Scholars (University of Bradford)

Works count: 18

Citation count: 219

H-index: 10

I10-index: 10